A citation-based method for searching scientific literature

Mingzhao Xing. Nat Rev Cancer 2013
Times Cited: 769







List of co-cited articles
568 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
29

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
456
16

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
785
16

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
713
15

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
13

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
704
11

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
827
11

BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
878
10

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
135
10

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
49
20

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
399
10

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
408
10

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
253
10

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A Knauf, Xiao-Hui Liao, Brian L West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen,[...]. J Clin Invest 2011
203
9

The changing incidence of thyroid cancer.
Cari M Kitahara, Julie A Sosa. Nat Rev Endocrinol 2016
343
9

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
379
8

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
322
8

Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
487
8

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
8

Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
Eleonora Molinaro, Cristina Romei, Agnese Biagini, Elena Sabini, Laura Agate, Salvatore Mazzeo, Gabriele Materazzi, Stefano Sellari-Franceschini, Alessandro Ribechini, Liborio Torregrossa,[...]. Nat Rev Endocrinol 2017
150
7


TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
178
7

Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
7

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Priyanka C Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D Williams, G Brandon Gunn, Horiana Grosu,[...]. J Immunother Cancer 2018
67
10

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
290
7


Current thyroid cancer trends in the United States.
Louise Davies, H Gilbert Welch. JAMA Otolaryngol Head Neck Surg 2014
858
7

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
147
7

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
7

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
57
12

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
136
7

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
6

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
683
6

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
302
6

Phase II trial of sorafenib in metastatic thyroid cancer.
Richard T Kloos, Matthew D Ringel, Michael V Knopp, Nathan C Hall, Mark King, Robert Stevens, Jiachao Liang, Paul E Wakely, Vasyl V Vasko, Motoyasu Saji,[...]. J Clin Oncol 2009
393
6

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Lola Rahib, Benjamin D Smith, Rhonda Aizenberg, Allison B Rosenzweig, Julie M Fleshman, Lynn M Matrisian. Cancer Res 2014
6

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
557
6

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
762
6

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
Seong-Keun Yoo, Seungbok Lee, Su-Jin Kim, Hyeon-Gun Jee, Byoung-Ae Kim, Hyesun Cho, Young Shin Song, Sun Wook Cho, Jae-Kyung Won, Jong-Yeon Shin,[...]. PLoS Genet 2016
137
6


Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Zhi Liu, Peng Hou, Meiju Ji, Haixia Guan, Kimberly Studeman, Kirk Jensen, Vasily Vasko, Adel K El-Naggar, Mingzhao Xing. J Clin Endocrinol Metab 2008
273
6

Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.
Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri. J Cancer Epidemiol 2013
649
6

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, YiYu Dong, Ed Reznik, Venkatraman Seshan, Gouri Nanjangud, Stephanie Eng, Promita Bose, Fengshen Kuo,[...]. Cancer Cell 2018
81
7

Recent incidences and differential trends of thyroid cancer in the USA.
Yushan Mao, Mingzhao Xing. Endocr Relat Cancer 2016
109
5

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
357
5

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J Sherman, Lara A Dunn, Alan L Ho, Shrujal S Baxi, Ronald A Ghossein, Matthew G Fury, Sofia Haque, Cami S Sima, Grace Cullen, James A Fagin,[...]. Cancer 2017
31
16

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Lindsey M Kelly, Guillermo Barila, Pengyuan Liu, Viktoria N Evdokimova, Sumita Trivedi, Federica Panebianco, Manoj Gandhi, Sally E Carty, Steven P Hodak, Jianhua Luo,[...]. Proc Natl Acad Sci U S A 2014
149
5

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
David G McFadden, Amanda Vernon, Philip M Santiago, Raul Martinez-McFaline, Arjun Bhutkar, Denise M Crowley, Martin McMahon, Peter M Sadow, Tyler Jacks. Proc Natl Acad Sci U S A 2014
80
6

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
221
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.